

Cloning, Nucleotide Sequencing, and Analysis of the Gene Encoding an AmpC β -Lactamase in *Acinetobacter baumannii*

GERMÁN BOU* AND JESÚS MARTÍNEZ-BELTRÁN

Servicio de Microbiología, Hospital Ramón y Cajal, 28034 Madrid, Spain

Received 13 January 1999/Returned for modification 29 August 1999/Accepted 5 November 1999

A clinical strain of *Acinetobacter baumannii* (strain Ab RYC 52763/97) that was isolated during an outbreak in our hospital and that was resistant to all β -lactam antibiotics tested produced three β -lactamases: a TEM-1-type (pI, 5.4) plasmid-mediated β -lactamase, a chromosomally mediated OXA-derived (pI, 9.0) β -lactamase, and a presumptive chromosomal cephalosporinase (pI, 9.4). The nucleotide sequence of the chromosomal cephalosporinase gene shows for the first time the gene encoding an AmpC β -lactamase in *A. baumannii*. In addition, we report here the biochemical properties of this *A. baumannii* AmpC β -lactamase.

Acinetobacter spp. are recognized as important opportunist pathogens mainly in immunocompromised patients (9, 10). Their contribution to nosocomial infection has increased over the past three decades (6, 7, 27), and several outbreaks of hospital infection have been reported worldwide (5; G. Bou, G. Cerveró, D. Malpica, M. Pérez-Vázquez, L. De Rafael, and J. Martínez-Beltrán, Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., abstr. K-120, 1998). Though prevalent in nature (4) and generally regarded as commensals of human skin and of the human respiratory tract (1, 15), they have been implicated as the cause of serious infectious diseases such as pneumonia, urinary tract infection, endocarditis, wound infection, meningitis, and septicemia, involving mostly patients with impaired host defenses (6, 9, 30). Antimicrobial treatment of serious infections due to *Acinetobacter*, particularly those caused by *Acinetobacter baumannii*, is complicated by the widespread multidrug resistance pattern of the organism (8, 18). With respect to β -lactam antibiotics, the most common mechanism of resistance is due to the synthesis of β -lactamases encoded either by the chromosome or by plasmids (9). So far, several class A and class D plasmid-encoded β -lactamases conferring different phenotypes of resistance to *A. baumannii* have been described (9, 24, 31, 32; G. Bou, A. Oliver, and J. Martínez-Beltrán, submitted for publication). Likewise, different chromosomally mediated cephalosporinases (pI, >8) have also been reported (9, 25), and sometimes these cephalosporinases have been particularly difficult to visualize by isoelectric focusing (24). In any case, nucleotide sequencing of the *ampC* gene has never been described. The main objective of this work was to clone and sequence the gene encoding the chromosomally mediated AmpC β -lactamase from a multiresistant *A. baumannii* clinical strain (Ab RYC 52763/97) isolated during an outbreak at our hospital in 1997 (Bou et al., 38th ICAAC). A detailed description of its biochemical characteristics is also provided.

The susceptibility testing of the Ab RYC 52763/97 strain was performed by an agar dilution method, as recommended by the National Committee for Clinical Laboratory Standards (23), using Mueller-Hinton agar and an inoculum size of 10^4 CFU per spot. Antibiotics were kindly provided as powders of a fixed

potency by their corresponding manufacturers. The antibiotic susceptibility profiles of all strains included in this study are shown in Table 1. The strain Ab RYC 52763/97 was highly resistant to all β -lactam antibiotics tested, with minimum inhibitory concentrations (MICs) of imipenem and meropenem being 128 and 256 μ g/ml, respectively.

β -Lactamases were analyzed by isoelectric focusing as described by Matthew et al. (22). The sonicated extract of strain Ab RYC 52763/97 contained three β -lactamases, as follows: one yielded a band with a pI of 5.4 and was cloned after amplification with *bla*_{TEM} primers C1 (5'-GGGAATTCTCGGG GAAATGTGCGCGGAAC) and C2 (5'-GGGATCCGAGTA AACTTGGTCTGACAG) (TEM-1 type); a second focused at a pI of 9.0, and after cloning (clone pBMB-1), the gene nucleotide sequence showed homology with those of OXA-derived

TABLE 1. MICs of β -lactams

Antibiotic	MIC (μ g/ml) ^a			
	<i>A. baumannii</i> RYC 52763/97	<i>E. coli</i> TG1	<i>E. coli</i> TG1 (pGER1)	<i>E. coli</i> TG1 (pGER2)
Ampicillin	>1,024	4	128	>1,024
Ampicillin plus clavulanic acid ^b	>1,024	4	64	128
Ampicillin plus sulbactam ^b	>1,024	2	16	>1,024
Ampicillin plus tazobactam ^b	>1,024	2	32	64
Ticarcillin	>1,024	4	32	>1,024
Cefazolin	>256	8	>256	>256
Cefuroxime	>256	4	>256	>256
Cefoxitin	>256	4	4	4
Cefotaxime	>256	≤0.125	4	8
Cefotaxime plus clavulanic acid	>256	≤0.125	2	4
Cefotaxime plus sulbactam	>256	≤0.125	0.25	2
Cefotaxime plus tazobactam	>256	≤0.125	0.5	1
Ceftazidime	>256	≤0.125	16	32
Ceftazidime plus clavulanic acid	>256	≤0.125	8	16
Ceftazidime plus sulbactam	>256	≤0.125	1	8
Ceftazidime plus tazobactam	>256	≤0.125	2	4
Cefepime	256	≤0.125	0.25	0.5
Aztreonam	>256	≤0.125	1	4
Imipenem	128	0.25	0.25	0.25
Meropenem	256	0.03	0.03	0.03

^a Enzymes are as follows: for *A. baumannii* RYC 52763/97, AmpC plus a β -lactamase with a pI of 9.0 plus TEM-1; for *E. coli* TG1 (pGER1), AmpC; and for *E. coli* TG1 (pGER2), AmpC plus TEM-1. Clone *E. coli* TG1 (pGER2) harbored the *ampC* gene in the pUC18 multicopy plasmid (containing the *bla*_{TEM-1} resistance marker).

^b Concentration of β -lactamase inhibitor was 4 μ g/ml.

* Corresponding author. Present address: Department of Immunology and Division of Infectious Diseases, Mayo Clinic, 200 First St. SW, Guggenheim 516, Rochester, MN 55905. Phone: (507) 284-9504. Fax: (507) 284-3757. E-mail: germanbou@mailcity.com.

AACTCATTG	AGATGTGTCA	TAGTATTCGT	CGTTAGAAAA	CAATTATTATG	50										
ACATTATTT	CAATGAGTTA	TCTATTTTTTA	TCGTGTACAG	<u>AGGAGCTAATC</u>	100										
				S.D.											
ATG	CGA	TTT	AAA	AAA	ATT	TCT	TGT	CTA	CTT	TTA	TCC	CCG	CTT	TTT	145
M	R	F	K	K	I	S	C	L	L	L	S	P	L	F	
ATT	TTT	AGT	ACC	TCA	ATT	TAT	GCG	GGC	AAT	ACA	CCA	AAA	GAC	CAA	190
I	F	S	T	S	I	Y	A	G	N	T	P	K	D	Q	
GAA	ATT	AAA	AAA	CTG	GTA	GAT	CAA	AAC	TTT	AAA	CCG	TTA	TTA	GAA	235
E	I	K	K	L	V	D	Q	N	F	K	P	L	L	E	
AAA	TAT	GAT	GTG	CCA	GGT	ATG	GCT	GTG	GGT	GTT	ATT	CAA	AAT	AAT	280
K	Y	D	V	P	G	M	A	V	G	V	I	Q	N	N	
AAA	AAG	TAT	GAA	ATG	TAT	TAT	GGT	CTT	CAA	TCT	GTT	CAA	GAT	AAA	325
K	K	Y	E	M	Y	Y	G	L	Q	S	V	Q	D	K	
AAA	GCC	GTA	AAT	AGC	AGT	ACT	ATT	TTT	GAG	CTA	GGT	TCT	GTC	AGT	370
K	A	V	N	S	S	T	I	F	E	L	G	S	V	S	
AAA	TTA	TTT	ACC	GCG	ACA	GCA	GGT	GGA	TAT	GCA	AAA	AAT	AAA	GGA	415
K	L	F	T	A	T	A	G	G	Y	A	K	N	K	G	
AAA	ATC	TCT	TTT	GAC	GAT	ACG	CCT	GGT	AAG	TAT	TGG	AAA	GAA	CTA	460
K	I	D	V	P	G	M	A	V	G	V	I	Q	N	N	
AAA	AAT	ACA	CCG	ATT	GAC	CAA	GTT	<u>AAC</u>	<u>TTA</u>	<u>CTT</u>	<u>CAA</u>	<u>CTC</u>	<u>GCG</u>	<u>ACG</u>	505
K	N	T	P	I	D	Q	V	N	L	L	Q	L	A	T	
TAT	ACA	AGT	GGT	AAC	CTT	GCC	TTG	CAA	TTT	CCA	GAT	GAA	GTA	AAA	550
Y	T	S	G	N	L	A	L	Q	F	P	D	E	V	K	
ACA	GAT	CAG	CAA	GTT	TTA	ACA	TTT	TTT	AAA	GAC	TGG	AAA	CCT	AAA	595
T	D	Q	Q	V	L	T	F	F	K	D	W	K	P	K	
AAC	TCA	ATC	GGT	GAA	TAT	CGA	CAA	TAT	TCA	AAC	CCA	AGC	ATT	GGT	640
N	S	I	G	E	Y	R	Q	Y	S	N	P	S	I	G	
TTA	TTT	GGA	AAA	GTT	GTA	GCT	TTG	TCT	ATG	<u>AAT</u>	<u>AAA</u>	<u>CCT</u>	<u>TTC</u>	<u>GAC</u>	685
L	F	G	K	V	V	A	L	S	M	N	K	P	F	D	
<u>CAA</u>	<u>GTC</u>	TTA	GAA	AAA	ACA	ATT	TTT	CCG	GCC	CTT	GGC	TTA	AAA	CAT	730
Q	V	L	E	K	T	I	F	P	A	L	G	L	K	H	
AGC	TAT	GTA	AAT	GTA	CCT	AAG	ACC	CAG	ATG	CAA	AAC	TAT	GCT	TTT	775
S	Y	V	N	V	P	K	T	Q	M	Q	N	Y	A	F	
GGC	TAT	AAC	CAA	GAA	AAT	CAG	CCG	ATT	CGA	GTT	AAC	CCC	GGC	CCA	820
G	Y	N	Q	E	N	Q	P	I	R	V	N	P	G	P	
CTC	GGT	GCC	CCA	GCA	TAT	GGC	GTC	AAA	TCG	ACA	CTA	CCC	GAC	ATG	865
L	G	A	P	A	Y	G	V	K	S	T	L	P	D	M	
TTG	AGT	TTT	ATT	CAT	GCC	<u>AAC</u>	<u>CTA</u>	<u>AAT</u>	<u>CCA</u>	<u>CAA</u>	AAA	TAT	CCA	GCA	910
L	S	F	I	H	A	N	L	N	P	Q	K	Y	P	A	
GAT	ATT	CAA	CGG	GCA	ATT	AAT	GAA	ACA	CAT	CAG	GGT	CGC	TAT	CAA	955
D	I	Q	R	A	I	N	E	T	H	Q	G	R	Y	Q	
GTA	AAT	ACC	ATG	TAT	CAG	GCA	CTC	GGT	TGG	GAA	GAG	TTT	TCT	TAT	1000
V	N	T	M	Y	Q	A	L	G	W	E	E	F	S	Y	
CCG	GCA	ACG	TTA	CAA	ACT	TTA	TTA	GAC	AGT	AAT	TCA	GAA	CAG	ATT	1045
P	A	T	L	Q	T	L	L	D	S	N	S	E	Q	I	
GTG	ATG	AAA	CCT	AAT	AAA	GTG	ACT	GCT	ATT	TCA	AAG	GAA	CCT	TCA	1090
V	M	K	P	N	K	V	T	A	I	S	K	E	P	S	
GTT	AAG	ATG	TAC	CAT	AAA	ACT	GGC	TCA	ACT	AAC	CGT	<u>TTC</u>	<u>GGA</u>	<u>ACA</u>	1135
V	K	M	Y	H	K	T	G	S	T	N	R	F	G	T	
<u>TAT</u>	<u>GTG</u>	<u>GTG</u>	<u>TTT</u>	<u>ATT</u>	CCT	AAA	GAA	AAT	ATT	GGT	TTA	GTC	ATG	TTA	1180
Y	V	V	F	I	P	K	E	N	I	G	L	V	M	L	
ACC	AAT	AAA	CGT	ATT	CCA	AAT	GAA	GAG	CGC	ATT	AAG	GCA	GCT	TAT	1225
T	N	K	R	I	P	N	E	E	R	I	K	A	A	Y	
GCT	GTG	CTG	AAT	GCA	ATA	AAG	AAA	TAA	TTTTTCCCTA	AAATAAAAAA					1272
A	V	L	N	A	I	K	K	-							
<u>AGAGAAATAG</u>	<u>TCATCATCTA</u>	<u>TTTCTCTATT</u>	<u>TTTTATAGGT</u>	<u>ATATGTTTAA</u>											1322
<u>AAAGAACCAA</u>	<u>ACATATCCTA</u>	<u>AGCTT</u>													1347

FIG. 1. Nucleotide sequence of the *ampC* gene. The deduced amino acid sequence of AmpC β-lactamase is shown below the nucleotide triplets. The boldface ATG and TAA represent the initiation and termination codons, respectively. A putative Shine-Dalgarno (S.D.) ribosomal recognition site (underlined) is indicated. The positions of the primers used to sequence the gene are indicated by underlining with arrowheads. The β-lactamase active site S-V-S-K, the conserved triad K-T-G, and the class C typical motif Y-X-N are presented in boldface. A putative terminator sequence is underlined.

β-lactamases (Bou et al., submitted); and the third focused at a pI of 9.4 and likely corresponded to a chromosomal cephalosporinase. With the *A. baumannii* clinical strain no transfer of resistance phenotype was observed in conjugation experiments. By alkaline lysis (28), a plasmid of 22 kb was isolated in this strain. By enzymatic restriction and ligation techniques (28) only a TEM-1 gene was found in this plasmid.

Chromosomal DNA of Ab RYC 52763/97 was prepared

by the method of Grimont and Grimont (16), digested with *Hind*III (Boehringer-Mannheim, Mannheim, Germany), and ligated into the *Hind*III site of pBGS18⁻ (29). Recombinant plasmids were introduced into *Escherichia coli* TG1 by transformation with CaCl₂ (28), and transformants were selected on Luria-Bertani agar plates supplemented with ampicillin (25 μg/ml) and kanamycin (50 μg/ml). Three *E. coli* transformants were obtained on selective medium supplemented with the antibi-

TABLE 2. Percent identity of amino acid sequences of *A. baumannii* AmpC and other class C β -lactamases

β -Lactamase (reference)	% Identity with:						
	<i>A. baumannii</i> AmpC	<i>A. sobria</i> AmpC	CMY-1	<i>S. marcescens</i> AmpC	FOX-2	FOX-3	<i>P. aeruginosa</i> AmpC
<i>A. baumannii</i> AmpC	100	42.3	41.8	41.7	41.3	41.0	40.5
<i>A. sobria</i> AmpC (26)		100	74.5	46.9	77.2	75.3	55.5
CMY-1 (2)			100	48.7	74.3	72.4	57.9
<i>S. marcescens</i> AmpC ^a				100	46.6	46.1	48.8
FOX-2 (3)					100	96.3	54.7
FOX-3 (20)						100	54.4
<i>P. aeruginosa</i> AmpC (19)							100

^a EMBL accession no. AB008454.

otics mentioned above. They harbored a recombinant plasmid, designated pGER1, with an insert of about 2.2 kb.

The β -lactam susceptibility pattern of the three transformants was identical, displaying resistance to ampicillin, cefazolin, cefuroxime, and, to a lesser extent, ceftazidime, while the susceptibility to the remaining β -lactams tested was differently affected by the presence of the recombinant plasmid pGER1 (Table 1). The MICs of ticarcillin, cefotaxime, cefepime, and aztreonam for *E. coli* TG1(pGER1) were increased, whereas the MICs of ceftazidime, imipenem, and meropenem remained unchanged. Regarding the effect of the β -lactamase inhibitors sulbactam and tazobactam, the MICs of ampicillin, cefotaxime, and ceftazidime decreased by 4- to 16-fold, in contrast with the very slight effect obtained with clavulanic acid. By isoelectric focusing, the single band of β -lactamase activity in the *E. coli* transformant cofocused with the β -lactamase (pI, 9.4) of the wild-type strain (results not shown).

In order to perform the sequencing reactions the 2.2-kb insert from the plasmid pGER1 was cloned in the pUC18 multicopy plasmid (29), resulting in the plasmid pGER2. Sequencing was carried out with the *Taq* DyeDeoxiTerminator Cycle Sequencing Kit and with primers specific to the coding sequence, and the sequence was analyzed in an automatic DNA sequencer (377 Abi-Prims; Perkin-Elmer). The entire sequence of the fragment was determined twice for accuracy.

The sequenced fragment was 2,195 bp long and contained only one open reading frame (ORF) (Fig. 1). An ATG codon initiated an 1,152-bp ORF which ended with a TAA codon (383 amino acids long). The initiation codon was preceded by a Shine-Dalgarno ribosome-binding sequence, AGGAG. GenBank database searches with this ORF revealed similarities with several class C chromosomal and plasmid-mediated β -lactamases (Table 2). The highest identity (40.5 to 42.3%) was observed with the following β -lactamases: AmpC of *Aeromonas sobria*, CMY-1, AmpC of *Serratia marcescens*, FOX-2, FOX-3, and AmpC of *Pseudomonas aeruginosa*; 35 to 40% identity was seen for AmpC β -lactamases from *E. coli*, *Proteus stuartii*, *Yersinia enterocolitica*, *Morganella morgani*, *Enterobacter cloacae*, and *Citrobacter freundii*. The deduced peptide sequence contained conserved motifs found in serine β -lactamases (14), as follows: the SXXS motif of the active site of AmpC, the class C typical motif YXN, and the KTG domain. The nucleotide sequence of the flanking regions of the *ampC* gene (about 400 bp on each side) did not show inverted repeated sequences suggestive of the presence of a transposable element. This *ampC* gene was probably not inserted in an integron, since the 59-base element (specific to gene cassettes inserted in integron structures) was not observed on the flanking regions.

The synthesis of chromosomal AmpC β -lactamases in some gram-negative rods such as *E. cloacae*, *C. freundii*, and *P. aeruginosa* may be inducible and involves genes such as the repres-

or *ampR* and *ampD*. The first is located immediately upstream from the *ampC* gene and is divergently transcribed (19). Sequencing of the flanking regions of the gene encoding the AmpC β -lactamase produced by the Ab RYC 52763/97 strain did not show homology with the *ampR* regulatory gene. Induction experiments with ceftazidime (one-half of the MIC) performed with the *E. coli* transformant carrying the *ampC* gene and with the original Ab RYC 52763/97 strain did not show an increase in the synthesis of the AmpC β -lactamase, determined as specific enzymatic activity, when the inducer was added (data not shown). These experiments indicated that the *A. baumannii* AmpC β -lactamase in this strain is noninducible.

The substrate profile of the AmpC β -lactamase was determined with the enzyme partially purified by G-75 Sephadex (Pharmacia Fine Chemicals AB, Uppsala, Sweden). Initial hydrolysis rates were monitored spectrophotometrically (UVIKON-930) at 25°C in 0.05 M phosphate buffer (pH 7.4), as described previously (12). The V_{\max} values indicate that cephaloridine is hydrolyzed more quickly than ampicillin and that ceftazidime and imipenem are not hydrolyzed at detectable levels (Table 3). Inhibition studies showed that the remaining β -lactamase activities in the presence of 100 μ M each inhibitor were as follows: clavulanic acid, 91%; sulbactam, 40%; and tazobactam, 45%. The 50% inhibitory concentrations (IC_{50} s) were obtained from semilogarithmic plots of enzymatic activity against inhibitor concentration. The IC_{50} s were 270 μ M for clavulanic acid, 7 μ M for sulbactam, and 8 μ M for tazobactam. These results correlated with the decrease in the MICs of ampicillin, cefotaxime, and ceftazidime in combination with these inhibitors against *E. coli* TG1 harboring AmpC β -lactamase (pGER1).

TABLE 3. Kinetic and inhibition parameters of the *A. baumannii* AmpC β -lactamase^a

Antibiotic	K_m (μ M)	V_{\max} (μ mol/ min/ μ l)	Relative V_{\max}^b	IC_{50} (μ M)
Cephaloridine	960	5,000	100	
Ampicillin	38	380	7.6	
Ceftazidime	14	52	1.0	
Cefotaxime	7.0	25	0.5	
Ceftazidime		<1	<0.01	
Imipenem		<1	<0.01	
Clavulanic acid				270 ^c
Sulbactam				7 ^c
Tazobactam				8 ^c

^a Kinetic experiments were performed using a 7.45-mg/ml proteic extract with a specific activity of 0.064 μ mol of nitrocefin hydrolyzed/min/ μ g of protein.

^b Obtained by normalizing the value for each antibiotic to that for cephaloridine (set to 100).

^c Nitrocefin (25 μ g/ml) was used as the substrate following 10 min preincubation of enzyme and inhibitor.




FIG. 2. Detection of the *ampC* gene in different *A. baumannii* isolates. The amplified products were resolved by 1.5% agarose gel electrophoresis and stained with ethidium bromide (50 μ g/ml). Lanes 1 and 11, DNA molecular weight markers III and V, respectively (Boehringer-Mannheim); lane 2, negative control (genomic DNA of *Listeria monocytogenes* amplified with primers P1 and P2); lanes 3 to 8, *A. baumannii* strains (Ab 1 to 6); lane 9, *A. junii* strain; lane 10, positive control (strain Ab RYC 52763/97).

In order to detect the *ampC* gene in different *A. baumannii* isolates, a PCR assay was performed. Six genotypically different *A. baumannii* strains (REP-PCR tested) with different antibiotic susceptibility patterns that had been collected in our hospital during the previous five years were used. The reactions were carried out with a 50- μ l volume of a reaction mixture containing 20 mM Tris-HCl (pH 8.8), 100 mM potassium chloride, 2.0 mM magnesium chloride, 200 μ M deoxynucleotide triphosphate, 50 pmol of each primer, 500 ng of the chromosomal DNA, and 2.5 U of *Taq* polymerase (Roche). The primers of the *ampC* coding region, P1 (5'-TAAACACC ACATATGTTCCG) and P2 (5'-ACTTACTTCAACTCGCG ACG), were used. Amplification reactions were submitted to the following program: initial denaturation (4 min at 94°C) followed by 30 cycles of denaturation (1 min at 94°C), annealing (1 min at 50°C), and extension (2 min at 72°C), with a single extension of 10 min at 72°C. The amplified 663-bp product was resolved by electrophoresis in a 1.5% (wt/vol) agarose gel containing ethidium bromide (50 μ g/ml). As shown in Fig. 2, the *ampC* gene was extensively spread between the six *A. baumannii* isolates but not in *Acinetobacter junii*. This result strongly suggests that the AmpC β -lactamase may play a role in the β -lactam resistance of *A. baumannii*.

The presence of chromosomal β -lactamases in the genus *Acinetobacter* was first suggested by Matthew and Harris (21). By examining β -lactamases from 30 strains of *Acinetobacter*, Joly-Guillou et al. (17) revealed a cephalosporinase with a pI of >8.0 in all these strains. Afterwards, Blechschmidt et al. (11) reported the purification and biochemical characterization of an extracellular β -lactamase with a pI of 9.3 produced by *Acinetobacter calcoaceticus*. Other attempts have been carried out in order to characterize the *A. baumannii* cephalosporinase biochemically (25), but nothing has been reported about the gene encoding the enzyme. The present study describes the genetic and biochemical characteristics of the *A. baumannii* AmpC β -lactamase. The following important features are noteworthy. (i) The amino acid sequence is closely related to the class C cephalosporinases, and the highest similarity was obtained with the *A. sobria* AmpC β -lactamase. (ii) The enzyme shows a typical cephalosporinase substrate profile (13). (iii) Enzymatic inhibition assays and antibiotic susceptibility studies showed a moderate inhibitory effect of sulbactam and tazobactam against *A. baumannii* AmpC β -lactamase. As for clavulanic acid, only a very slight inhibitory effect was observed. (iv) No AmpC β -lactamase induction was observed

when cefoxitin was added, and no *ampR* sequences were found on the flanking regions of the *ampC* gene. Nevertheless, whether a regulatory AmpR-like protein gene exists in *A. baumannii*, although not adjacent to the *ampC* gene, remains to be elucidated.

Certainly, resistance to β -lactam antibiotics in *A. baumannii* is a multifactorial problem involving resistance mechanisms in addition to β -lactamases (9); thus, in our study, the β -lactam MICs conferred by the AmpC β -lactamase, even by means of a multicopy plasmid carried by *E. coli* TG1, did not reach the high MICs observed for the Ab RYC 52763/97 clinical strain (MICs conferred by the OXA-derived β -lactamase [Bou et al., submitted] are not relevant when compared with the *A. baumannii* clinical strain). Note also that the MICs of the carbapenems were not affected by the presence of the AmpC β -lactamase even in a multicopy plasmid. Nevertheless, the presence of the *ampC* gene in all six different *A. baumannii* strains tested suggests that the AmpC β -lactamase, in combination with other β -lactam resistance mechanisms, may play an important role in β -lactam resistance in *A. baumannii*.

In summary, we report here for the first time the cloning, sequencing, and analysis of the *ampC* gene and the biochemical characterization of the AmpC β -lactamase from an *A. baumannii* clinical strain.

Nucleotide sequence accession number. The nucleotide sequence of the *ampC* gene has been given the EMBL database accession no. AJ009979.

We thank L. de Rafael for his critical reading.

REFERENCES

- Al-Khoja, M. S., and J. H. Darrell. 1979. The skin as the source of *Acinetobacter* and *Moraxella* species occurring in blood cultures. *J. Clin. Pathol.* **32**:497-499.
- Bauernfeind, A., I. Stemplinger, R. Jungwirth, R. Wilhem, and Y. Chong. 1996. Comparative characterization of the cephamycinase *bla*_{CMY-1} gene and its relationship with other β -lactamase genes. *Antimicrob. Agents Chemother.* **40**:1926-1930.
- Bauernfeind, A., S. Wagner, R. Jungwirth, J. Schneider, and D. Meyer. 1997. A novel class C β -lactamase (FOX-2) in *Escherichia coli* conferring resistance to cephamycins. *Antimicrob. Agents Chemother.* **41**:2041-2046.
- Baumann, P. 1968. Isolation of *Acinetobacter* from soil and water. *J. Bacteriol.* **96**:39-42.
- Bergogne-Bérézin, E. 1995. The increasing significance of outbreaks of *Acinetobacter* spp.: the need for control and new agents. *J. Hosp. Infect.* **30**:441-452.
- Bergogne-Bérézin, E., M. L. Joly-Guillou, and J. F. Vieu. 1987. Epidemiology of nosocomial infections due to *Acinetobacter calcoaceticus*. *J. Hosp. Infect.* **10**:105-113.

7. Bergogne-Bérézin, E., and M. L. Joly-Guillou. 1985. An underestimated nosocomial pathogen, *Acinetobacter calcoaceticus*. J. Antimicrob. Chemother. **16**:535–538.
8. Bergogne-Bérézin, E., and M. L. Joly-Guillou. 1986. Comparative activity of imipenem, ceftazidime and cefotaxime against *Acinetobacter calcoaceticus*. J. Antimicrob. Chemother. **18**(Suppl. E):35–39.
9. Bergogne-Bérézin, E., and K. J. Towner. 1996. *Acinetobacter* spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev. **9**:148–165.
10. Bergogne-Bérézin, E., M. L. Joly-Guillou, and K. J. Towner. 1996. History and importance of *Acinetobacter* spp.: role in infections, treatment and cost implications, p. 1–12. In E. Bergogne-Bérézin et al. (ed.), *Acinetobacter*: microbiology, epidemiology, infections, management. CRC Press, Boca Raton, Fla.
11. Blechschmidt, B., P. Borneleit, and H. P. Kleber. 1992. Purification and characterization of an extracellular β -lactamase produced by *Acinetobacter calcoaceticus*. J. Gen. Microbiol. **138**:1197–1202.
12. Bou, G., J. Martínez-Beltrán, G. Cerveró, and J. C. Pérez-Díaz. 1999. Biochemical and genetic characteristics of TEM-29B, a novel extended spectrum β -lactamase. FEMS Microbiol. Lett. **174**:185–190.
13. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for β -lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. **39**:1211–1233.
14. Ghuysen, J. M. 1991. Serine β -lactamases and penicillin-binding proteins. Annu. Rev. Microbiol. **45**:37–67.
15. Glew, R. H., R. C. Moellering, and L. J. Kunz. 1977. Infections with *Acinetobacter calcoaceticus* (*Herellea vaginicola*): clinical and laboratory studies. Medicine **56**:79–97.
16. Grimont, F., and P. A. D. Grimont. 1986. Ribosomal nucleic acid gene restriction patterns as potential taxonomic tools. Ann. Inst. Pasteur Microbiol. **137B**:165–175.
17. Joly-Guillou, M. L., E. Bergogne-Bérézin, and N. Moreau. 1987. Enzymatic resistance to β -lactams and aminoglycosides in *Acinetobacter calcoaceticus*. J. Antimicrob. Chemother. **20**:773–775.
18. Joly-Guillou, M. L., E. Bergogne-Bérézin, and J. F. Vieu. 1990. Epidemiologie et résistance aux antibiotiques des *Acinetobacter* en milieu hospitalier. Presse Med. **19**:357–361.
19. Lodge, J. M., S. D. Minchin, L. Piddock, and J. W. Busby. 1990. Cloning, sequencing and analysis of the structural gene and regulatory region of the *Pseudomonas aeruginosa* chromosomal ampC β -lactamase. Biochem. J. **272**:627–631.
20. Marchese, A., G. Arlet, G. C. Schito, P. H. Lagrange, and A. Philippon. 1998. Characterization of FOX-3, an AmpC-type plasmid-mediated β -lactamase from an Italian isolate of *Klebsiella oxytoca*. Antimicrob. Agents Chemother. **42**:464–467.
21. Matthew, M., and A. M. Harris. 1976. Identification of β -lactamase by analytical isoelectric focusing: correlation with bacterial taxonomy. J. Gen. Microbiol. **94**:55–67.
22. Matthew, M., A. M. Harris, M. J. Marshall, and G. W. Ross. 1975. The use of analytical isoelectric focusing for detection and identification of β -lactamases. J. Gen. Microbiol. **88**:169–178.
23. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
24. Paton, R., R. S. Miles, J. Hood, and S. G. B. Amyes. 1993. ARI 1: β -lactamase-mediated imipenem resistance in *Acinetobacter baumannii*. Int. J. Antimicrob. Agents **2**:81–88.
25. Perilli, M., A. Felici, A. Oratore, G. Cornaglia, G. Bofiglio, G. M. Rossolini, and G. Amicosante. 1996. Characterization of the chromosomal cephalosporinase produced by *Acinetobacter lwoffii* and *Acinetobacter baumannii* clinical isolates. Antimicrob. Agents Chemother. **40**:715–719.
26. Rasmussen, B. A., D. Keeney, Y. Yang, and K. Bush. 1994. Cloning and expression of a cloxacillin-hydrolyzing enzyme and a cephalosporinase from *Aeromonas sobria* AER 14M in *Escherichia coli*: requirement for an *E. coli* chromosomal mutation for efficient expression of the class D enzyme. Antimicrob. Agents Chemother. **38**:2078–2085.
27. Retailliau, H. F., A. W. Hightower, R. E. Dixon, and J. R. Allen. 1979. *Acinetobacter calcoaceticus*: a nosocomial pathogen with an unusual seasonal pattern. J. Infect. Dis. **139**:371–375.
28. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
29. Spratt, B. G., P. J. Hedge, T. S. Heesen, A. Edelman, and J. K. Broome-Smith. 1986. Kanamycin-resistant vectors that are analogues of plasmids pUC8, pUC9, pEMBL8, and pEMBL9. Gene **41**:337–342.
30. Tilley, P. A. G., and F. J. Roberts. 1994. Bacteremia with *Acinetobacter* species: risk factors and prognosis in different clinical settings. Clin. Infect. Dis. **18**:896–900.
31. Vahaboglu, H., R. Öztürk, G. Aygün, F. Coşkun, A. Yaman, A. Kaygusuz, H. Leblebicioglu, I. Balik, K. Aydın, and M. Otkun. 1997. Widespread detection of PER-1-type extended-spectrum β -lactamases among nosocomial *Acinetobacter* and *Pseudomonas aeruginosa* isolates in Turkey: a nationwide multicenter study. Antimicrob. Agents Chemother. **41**:2265–2269.
32. Vila, J., M. Navia, J. Ruiz, and C. Casals. 1997. Cloning and nucleotide sequence analysis of a gene encoding an OXA-derived β -lactamase in *Acinetobacter baumannii*. Antimicrob. Agents Chemother. **41**:2757–2759.